Monday, September 20, 1999 Published at 12:06 GMT 13:06 UK
Plan to block patenting of human genes
The company Celera aims to be "the definitive source of genomic information"
The UK and US governments are planning an agreement to prevent the 100,000 human genes being patented by private companies.
A first draft of the human genome is expected early next year. Critics of gene patents say that the licences that would then be required would make it too expensive for new treatments and cures to be developed.
But drug companies have argued in the past that, without patenting, they cannot fund the expensive drug research required, as they have no guarantee of recovering their investment.
The UK-owned Wellcome Trust and the US National Institute of Health (NIH) already make each gene public within 24 hours of its discovery, which prevents patenting unless a company has already filed patent applications.
The new proposal would probably be a strong statement against patenting. Legislation is less likely due to the long time it would take to pass.
Dr Michael Morgan is chief executive of the Wellcome Trust's Genome Campus, Cambridge, UK, which is carrying out a large part of the international Human Genome Project. He told the BBC: "This would be a tremendous step forward in ensuring that this information, which belongs to all of us, would be made freely available."
"A strong statement would send a very powerful message to future legislators and, indeed, to the lawyers who might well end up fighting cases in courts."
He did not believe the move would inhibit new medical discoveries, as a map of a gene does not reveal its function - that would remain to be discovered. What it would do, Dr Morgan said, was to "ensure that no one company can stop others working on a gene."
The plan has come to light through documents released to the UK's Guardian newspaper under US freedom of information law.
These show that Lord Sainsbury and Neal Lane, respectively science minister and adviser to the UK Prime Minister and US President, have had a number of discussions.
These are aimed at turning what is called the Bermuda agreement - an informal agreement not to patent and to make public all research on human genes - into a full intergovernmental agreement.
Celera accelerates worries
Much of the concern about human gene patenting has involved Craig Venter, a pioneering US scientist and entrepreneur. His company, Celera, has claimed it will sequence the 100,000 genes before an international collaboration, the Human Genome Project, does so. This could allow Professor Venter to patent the genes.
He had sought a patenting agreement with the US Department of Energy (DoE) to protect Celera's investment. But a released email says that agreement has been withdrawn and the US DoE is now "working with NIH and the Wellcome Trust as a group on any further agreements."
The UK Department of Trade and Industry has confirmed that negotiations on an intergovernmental agreement are taking place.